兴奋性氨基酸与缺血性脑卒中的研究进展
Research Progress of Excitatory Amino Acids and Ischemic Stroke
DOI: 10.12677/acm.2024.1451524, PDF,    科研立项经费支持
作者: 王杜君, 赵立波*：重庆医科大学附属永川医院神经内科，重庆
关键词: 缺血性脑卒中；兴奋性氨基酸；代谢组学；研究进展；Ischemic Stroke； Excitatory Amino Acid； Metabolomics； Research Progress
摘要: 卒中是全球第二大死亡原因，在我国也是导致成人残疾、死亡的首要疾病，其中最常见的卒中类型是急性缺血性脑卒中。缺血性脑卒中(Ischemic stroke, IS)是由血管内血栓形成或栓塞引起脑血流中断，使脑血流灌注下降，主要是以突然起病、局灶性神经功能缺损为特点的急性脑血管疾病。越来越多的研究表明，代谢紊乱与IS的发生、发展密切相关。有研究结果表明，兴奋性氨基酸代谢途径异常与IS的发生、发展密切相关。本综述探讨了兴奋性氨基酸在IS中的进展，强调了其在缺血性卒中的病理生理机制及目前作为潜在治疗靶点的可能性，并为进一步研究提供参考，对兴奋性氨基酸与缺血性脑卒中进行综述。
Abstract: Stroke is the second leading cause of death worldwide and the leading cause of disability and death in adults in China, with the most common type of stroke being acute ischemic stroke. Ischemic stroke (IS) is an acute cerebrovascular disease characterized mainly by sudden onset and focal neurological deficits due to interruption of cerebral blood flow caused by intravascular thrombosis or embolism, resulting in decreased cerebral perfusion. More and more studies have shown that metabolic disorders are closely related to the onset and progress of IS. Studies have shown that the abnormal excitatory amino acid metabolic pathway is closely related to the occurrence and development of IS. In this review, we discuss the progress of excitatory amino acids in IS, highlight the pathophysiological mechanism of excitatory amino acids in ischemic stroke and the possibility of their being potential therapeutic targets at present, and provide reference for further research.
文章引用：王杜君, 赵立波. 兴奋性氨基酸与缺血性脑卒中的研究进展[J]. 临床医学进展, 2024, 14(5): 1046-1054. https://doi.org/10.12677/acm.2024.1451524

参考文献

[1] Guo, J., Wang, J., Sun, W., et al. (2021) The Advances of Post-Stroke Depression: 2021 Update. Journal of Neurology, 269, 1236-1249. [Google Scholar] [CrossRef] [PubMed]
[2] Zhou, M., Wang, H., Zhu, J., et al. (2016) Cause-Specific Mortality for 240 Causes in China during 1990-2013: A Systematic Subnational Analysis for the Global Burden of Disease Study 2013. The Lancet, 387, 251-272.
[3] Naghavi, M., Abajobir, A.A., Abbafati, C., et al. (2017) Global, Regional, and National Age-Sex Specific Mortality for 264 Causes of Death, 1980-2016: A Systematic Analysis for the Global Burden of Disease Study 2016. The Lancet, 390, 1151-1210. [Google Scholar] [CrossRef] 
[4] (2018) Global, Regional, and Country-Specific Lifetime Risks of Stroke, 1990 and 2016. New England Journal of Medicine, 379, 2429-2437. [Google Scholar] [CrossRef] 
[5] Li, Y., Tang, Y. and Yang, G.-Y. (2021) Therapeutic Application of Exosomes in Ischaemic Stroke. Stroke and Vascular Neurology, 6, 483-495. [Google Scholar] [CrossRef] [PubMed]
[6] Mahmoud, S., Gharagozloo, M., Simard, C., et al. (2019) Astrocytes Maintain Glutamate Homeostasis in the CNS by Controlling the Balance between Glutamate Uptake and Release. Cells, 8, Article No. 184. [Google Scholar] [CrossRef] [PubMed]
[7] Andersen, J.V., Markussen, K.H., Jakobsen, E., et al. (2021) Glutamate Metabolism and Recycling at the Excitatory Synapse in Health and Neurodegeneration. Neuropharmacology, 196, Article ID: 108719. [Google Scholar] [CrossRef] [PubMed]
[8] Wang, X., Patel, N.D., Hui, D., et al. (2014) Gene Expression Patterns in the Hippocampus during the Development and Aging of Glud1(Glutamate Dehydrogenase 1) Transgenic and Wild Type Mice. BMC Neuroscience, 15, Article No. 37. [Google Scholar] [CrossRef] [PubMed]
[9] Gasparini, C.F., Sutherland, H.G., Haupt, L.M., et al. (2013) Genetic Analysis of GRIA2 and GRIA4 Genes in Migraine. Headache: The Journal of Head and Face Pain, 54, 303-312. [Google Scholar] [CrossRef] [PubMed]
[10] Magi, S., Piccirillo, S. and Amoroso, S. (2019) The Dual Face of Glutamate: From a Neurotoxin to a Potential Survival Factor—Metabolic Implications in Health and Disease. Cellular and Molecular Life Sciences, 76, 1473-1488. [Google Scholar] [CrossRef] [PubMed]
[11] Szczurowska, E. and Mareš, P. (2013) NMDA and AMPA Receptors: Development and Status Epilepticus. Physiological Research, 62, S21-S38. [Google Scholar] [CrossRef] [PubMed]
[12] Nadler, J.V. (2010) Aspartate Release and Signalling in the Hippocampus. Neurochemical Research, 36, 668-676. [Google Scholar] [CrossRef] [PubMed]
[13] Hayashi, M. (2018) Structure-Function Relationship of Transporters in the Glutamate-Glutamine Cycle of the Central Nervous System. International Journal of Molecular Sciences, 19, Article No. 1177. [Google Scholar] [CrossRef] [PubMed]
[14] Shen, Z., Xiang, M., Chen, C., et al. (2022) Glutamate Excitotoxicity: Potential Therapeutic Target for Ischemic Stroke. Biomedicine & Pharmacotherapy, 151, Article ID: 113125. [Google Scholar] [CrossRef] [PubMed]
[15] He, S., Zhang, X. and Qu, S. (2018) Glutamate, Glutamate Transporters, and Circadian Rhythm Sleep Disorders in Neurodegenerative Diseases. ACS Chemical Neuroscience, 10, 175-181. [Google Scholar] [CrossRef] [PubMed]
[16] Dorsett, C.R., Mcguire, J.L., Depasquale, E.A.K., et al. (2017) Glutamate Neurotransmission in Rodent Models of Traumatic Brain Injury. Journal of Neurotrauma, 34, 263-272. [Google Scholar] [CrossRef] [PubMed]
[17] Swanson, R., Ying, W. and Kauppinen, T. (2004) Astrocyte Influences on Ischemic Neuronal Death. Current Molecular Medicine, 4, 193-205. [Google Scholar] [CrossRef] [PubMed]
[18] Takano, T., Oberheim, N., Cotrina, M.L., et al. (2009) Astrocytes and Ischemic Injury. Stroke, 40, S8-S12. [Google Scholar] [CrossRef] 
[19] Amantea, D. and Bagetta, G. (2017) Excitatory and Inhibitory Amino Acid Neurotransmitters in Stroke: From Neurotoxicity to Ischemic Tolerance. Current Opinion in Pharmacology, 35, 111-119. [Google Scholar] [CrossRef] [PubMed]
[20] Rodriguez-Chavez, V., Moran, J., Molina-Salinas, G., et al. (2021) Participation of Glutamatergic Ionotropic Receptors in Excitotoxicity: The Neuroprotective Role of Prolactin. Neuroscience, 461, 180-193. [Google Scholar] [CrossRef] [PubMed]
[21] Hansen, K.B., Wollmuth, L.P., Bowie, D., et al. (2022) Structure, Function, and Pharmacology of Glutamate Receptor Ion Channels. Pharmacological Reviews, 73, 1469-1658. [Google Scholar] [CrossRef] [PubMed]
[22] Wang, C., Liu, F., Patterson, T.A., et al. (2017) Relationship between Ketamine-Induced Developmental Neurotoxicity and NMDA Receptor-Mediated Calcium Influx in Neural Stem Cell-Derived Neurons. NeuroToxicology, 60, 254-259. [Google Scholar] [CrossRef] [PubMed]
[23] Rajani, V., Sengar, A.S. and Salter, M.W. (2020) Tripartite Signalling by NMDA Receptors. Molecular Brain, 13, Article No. 23. [Google Scholar] [CrossRef] [PubMed]
[24] Macdonald, J.F., Porietis, A.V. and Wojtowicz, J.M. (1982) L-Aspartic Acid Induces a Region of Negative Slope Conductance in the Current-Voltage Relationship of Cultured Spinal Cord Neurons. Brain Research, 237, 248-253. [Google Scholar] [CrossRef] [PubMed]
[25] Wang, R. and Reddy, P.H. (2017) Role of Glutamate and NMDA Receptors in Alzheimer’s Disease. Journal of Alzheimer’s Disease, 57, 1041-1048. [Google Scholar] [CrossRef] 
[26] Hanada, T. (2020) Ionotropic Glutamate Receptors in Epilepsy: A Review Focusing on AMPA and NMDA Receptors. Biomolecules, 10, Article No. 464. [Google Scholar] [CrossRef] [PubMed]
[27] 张欢欢, 高原雪, 何林, 等. EAAs在脑缺血损伤中的毒性作用及其干预药物[J]. 山东医药, 2018, 58(36): 106-109.
[28] Bodzęta, A., Scheefhals, N. and Macgillavry, H.D. (2021) Membrane Trafficking and Positioning of MGluRs at Presynaptic and Postsynaptic Sites of Excitatory Synapses. Neuropharmacology, 200, Article ID: 108799. [Google Scholar] [CrossRef] [PubMed]
[29] Zhang, Y., Chu, J. and Wong, G. (2022) Cerebral Glutamate Regulation and Receptor Changes in Perioperative Neuroinflammation and Cognitive Dysfunction. Biomolecules, 12, Article No. 597. [Google Scholar] [CrossRef] [PubMed]
[30] Cleva, R.M. and Olive, M.F. (2012) Metabotropic Glutamate Receptors and Drug Addiction. Wiley Interdisciplinary Reviews: Membrane Transport and Signaling, 1, 281-295. [Google Scholar] [CrossRef] [PubMed]
[31] Luessen, D.J. and Conn, P.J. (2022) Allosteric Modulators of Metabotropic Glutamate Receptors as Novel Therapeutics for Neuropsychiatric Disease. Pharmacological Reviews, 74, 630-661. [Google Scholar] [CrossRef] [PubMed]
[32] Zhang, X., Wang, D., Zhang, B., et al. (2020) Regulation of Microglia by Glutamate and Its Signal Pathway in Neurodegenerative Diseases. Drug Discovery Today, 25, 1074-1085. [Google Scholar] [CrossRef] [PubMed]
[33] Todd, A.C. and Hardingham, G.E. (2020) The Regulation of Astrocytic Glutamate Transporters in Health and Neurodegenerative Diseases. International Journal of Molecular Sciences, 21, Article No. 9607. [Google Scholar] [CrossRef] [PubMed]
[34] Lee, M., Ko, D.G., Hong, D.K., et al. (2020) Role of Excitatory Amino Acid Carrier 1 (EAAC1) in Neuronal Death and Neurogenesis after Ischemic Stroke. International Journal of Molecular Sciences, 21, Article No. 5676. [Google Scholar] [CrossRef] [PubMed]
[35] Rao, V.L.R., Dogan, A., Bowen, K.K., et al. (2008) Antisense Knockdown of the Glial Glutamate Transporter GLT-1 Exacerbates Hippocampal Neuronal Damage Following Traumatic Injury to Rat Brain. European Journal of Neuroscience, 13, 119-128. [Google Scholar] [CrossRef] [PubMed]
[36] Danbolt, N.C. (2001) Glutamate Uptake. Progress in Neurobiology, 65, 1-105. [Google Scholar] [CrossRef] 
[37] Wang, F., Xie, X., Xing, X., et al. (2022) Excitatory Synaptic Transmission in Ischemic Stroke: A New Outlet for Classical Neuroprotective Strategies. International Journal of Molecular Sciences, 23, Article No. 9381. [Google Scholar] [CrossRef] [PubMed]
[38] Nicholls, D.G. (2004) Mitochondrial Dysfunction and Glutamate Excitotoxicity Studied in Primary Neuronal Cultures. Current Molecular Medicine, 4, 149-177. [Google Scholar] [CrossRef] [PubMed]
[39] Gogvadze, V. and Orrenius, S. (2006) Mitochondrial Regulation of Apoptotic Cell Death. Chemico-Biological Interactions, 163, 4-14. [Google Scholar] [CrossRef] [PubMed]
[40] Duchen, M.R. (2004) Roles of Mitochondria in Health and Disease. Diabetes, 53, S96-S102. [Google Scholar] [CrossRef] 
[41] Binvignat, O. and Olloquequi, J. (2020) Excitotoxicity as a Target Against Neurodegenerative Processes. Current Pharmaceutical Design, 26, 1251-1262. [Google Scholar] [CrossRef] [PubMed]
[42] Minematsu, K., Fisher, M., Li, L., et al. (1993) Effects of a Novel NMDA Antagonist on Experimental Stroke Rapidly and Quantitatively Assessed by Diffusion-Weighted MRI. Neurology, 43, 397-403. [Google Scholar] [CrossRef] 
[43] Dohmen, C., Kumura, E., Rosner, G., et al. (2005) Extracellular Correlates of Glutamate Toxicity in Short-Term Cerebral Ischemia and Reperfusion: A Direct in Vivo Comparison between White and Gray Matter. Brain Research, 1037, 43-51. [Google Scholar] [CrossRef] [PubMed]
[44] Chen, B., Wang, G., Li, W., et al. (2017) Memantine Attenuates Cell Apoptosis by Suppressing the Calpain-Caspase-3 Pathway in an Experimental Model of Ischemic Stroke. Experimental Cell Research, 351, 163-172. [Google Scholar] [CrossRef] [PubMed]
[45] Ruan, L., Wang, Y., Chen, S, C., et al. (2017) Metabolite Changes in the Ipsilateral and Contralateral Cerebral Hemispheres in Rats with Middle Cerebral Artery Occlusion. Neural Regeneration Research, 12, 931-937. [Google Scholar] [CrossRef] [PubMed]
[46] Castillo, J., Davalos, A., Naveiro, J., et al. (1996) Neuroexcitatory Amino Acids and Their Relation to Infarct Size and Neurological Deficit in Ischemic Stroke. Stroke, 27, 1060-1065. [Google Scholar] [CrossRef] 
[47] 于岚, 武祺, 关颖, 等. 急性脑梗死患者脑脊液兴奋性氨基酸水平的变化及其临床意义[J]. 临床神经病学杂志, 2005, 18(5): 373-374.
[48] 武祺, 胡亮, 黄惠敏. 50例急性大脑皮层梗死患者脑脊液兴奋性氨基酸含量的研究[J]. 求医问药(学术版), 2011, 9(12): 217-218.
[49] Wang, X., Liu, T., Song, H., et al. (2019) Targeted Metabolomic Profiling Reveals Association between Altered Amino Acids and Poor Functional Recovery after Stroke. Frontiers in Neurology, 10, Article No. 1425. [Google Scholar] [CrossRef] [PubMed]
[50] Wang, X., Zhang, L., Sun, W., et al. (2020) Changes of Metabolites in Acute Ischemic Stroke and Its Subtypes. Frontiers in Neuroscience, 14, Article ID: 580929. [Google Scholar] [CrossRef] [PubMed]
[51] Liu, J., Yuan, J., Zhao, J., et al. (2021) Serum Metabolomic Patterns in Young Patients with Ischemic Stroke: A Case Study. Metabolomics, 17, Article No. 24. [Google Scholar] [CrossRef] [PubMed]
[52] 汤清平, 杨期东, 王改青, 等. AMPA受体亚单位GluR2在大鼠局灶性脑缺血不同时期表达及其机制研究[J]. 中国医学工程, 2006, 14(2): 131-136.
[53] 许位, 石秋艳, 孙原, 等. 新型AMPA受体拮抗剂对脑梗死再灌注损伤的保护作用[J]. 中风与神经疾病杂志, 2018, 35(8): 676-680.
[54] 刘佳雨, 严萍, 张瑜, 等. 代谢型谷氨酸受体在丰富环境改善卒中后认知功能障碍中的作用[J]. 中国组织工程研究, 2022, 26(23): 3676-3682.
[55] Rothstein, J.D., Patel, S., Regan, M.R., et al. (2005) Beta-Lactam Antibiotics Offer Neuroprotection by Increasing Glutamate Transporter Expression. Nature, 433, 73-77. [Google Scholar] [CrossRef] [PubMed]
[56] Feng, D., Wang, W., Dong, Y., et al. (2014) Ceftriaxone Alleviates Early Brain Injury after Subarachnoid Hemorrhage by Increasing Excitatory Amino Acid Transporter 2 Expression via the PI3K/Akt/NF-KappaB Signaling Pathway. Neuroscience, 268, 21-32. [Google Scholar] [CrossRef] [PubMed]
[57] Verma, R., Mishra, V., Sasmal, D., et al. (2010) Pharmacological Evaluation of Glutamate Transporter 1 (GLT-1) Mediated Neuroprotection Following Cerebral Ischemia/Reperfusion Injury. European Journal of Pharmacology, 638, 65-71. [Google Scholar] [CrossRef] [PubMed]
[58] Yu, P., Guan, L., Zhou, L., et al. (2017) Upregulation of Glutamate Metabolism by BYHWD in Cultured Astrocytes Following Oxygen-Glucose Deprivation/Reoxygenation in Part Depends on the Activation of P38 MAPK. Experimental and Therapeutic Medicine, 13, 3089-3096. [Google Scholar] [CrossRef] [PubMed]

为你推荐